Ajay Prakash

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4065460/publications.pdf

Version: 2024-02-01

81	1,302	18	32
papers	citations	h-index	g-index
85	85	85	2175
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Terpenoid analogues as putative therapeutic agents towards glutathione peroxidase (GPX4) in neurodegenerative disorders: a dynamic computational approach. Journal of Biomolecular Structure and Dynamics, 2023, 41, 5436-5446.	3.5	4
2	Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings. Journal of Biomolecular Structure and Dynamics, 2022, 40, 8894-8904.	3.5	20
3	Yogic Neti-Kriya Using Povidone Iodine: Can it have a Preventive Role Against SARS-CoV-2 Infection Gateway?. Indian Journal of Otolaryngology and Head and Neck Surgery, 2022, 74, 3186-3192.	0.9	5
4	Indomethacin: an exploratory study of antiviral mechanism and host-pathogen interaction in COVID-19. Expert Review of Anti-Infective Therapy, 2022, 20, 383-390.	4.4	11
5	Recent Advances in Molecular Pathways and Therapeutic Implications Targeting Mitochondrial Dysfunction for Alzheimer's Disease. Molecular Neurobiology, 2022, 59, 535-555.	4.0	41
6	An insight into the simulation directed understanding of the mechanism in SARS CoV-2 N-CTD, dimer integrity, and RNA-binding: Identifying potential antiviral inhibitors. Journal of Biomolecular Structure and Dynamics, 2022, 40, 13912-13924.	3.5	4
7	Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. Journal of Critical Care, 2022, 67, 172-181.	2.2	81
8	A systematic review on SARS-CoV-2 remission: an emerging challenge for its management, treatment, immunization strategies, and post-treatment guidelines. New Microbes and New Infections, 2022, 45, 100949.	1.6	1
9	Efficacy, tolerability and safety of perampanel in population with pharmacoresistant focal seizures: A systematic review and meta-analysis. Epilepsy Research, 2022, 182, 106895.	1.6	6
10	RATIONAL FOR CONTINUING TERLIPRESSIN AFTER ENDOSCOPIC VARICEAL LIGATION IN ACUTE VARICEAL HAEMORRHAGE NEEDS FURTHER EVIDENCE: A PILOT STUDY. Arquivos De Gastroenterologia, 2022, 59, 89-96.	0.8	3
11	A preliminary study to evaluate the behavior of Indian population toward E-pharmacy Indian Journal of Pharmacology, 2022, 54, 131-137.	0.7	3
12	In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N) Tj ETQq0 () 0.jgBT /C	Overlock 10 Tf
13	Efficacy and Safety of Topical Cysteamine in Corneal Cystinosis: A Systematic Review and Meta-Analysis. American Journal of Ophthalmology, 2021, 223, 275-285.	3.3	5
14	Questionnaire-based Pan-India survey for impact assessment of National Formulary of India. Indian Journal of Pharmacology, 2021, 53, 115.	0.7	1
15	Indian contribution toward biomedical research and development in COVID-19: A systematic review. Indian Journal of Pharmacology, 2021, 53, 63.	0.7	13
16	Current status of in silico, preclinical and clinical study registries across the globe: A systematic review and meta-analysis. Indian Journal of Pharmacology, 2021, 53, 160.	0.7	0
17	Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?. Medical Hypotheses, 2021, 149, 110539.	1.5	10
18	Everolimus: A potential therapeutic agent targeting PI3K/Akt pathway in brain insulin system dysfunction and associated neurobehavioral deficits. Fundamental and Clinical Pharmacology, 2021, 35, 1018-1031.	1.9	3

#	Article	IF	Citations
19	Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review. Biomedicine and Pharmacotherapy, 2021, 137, 111300.	5.6	21
20	nCoV-2019 infection induced neurological outcome and manifestation, linking its historical ancestor SARS-CoV and MERS-CoV: a systematic review and meta-analysis. Scientific Reports, 2021, 11, 12888.	3.3	5
21	Role of protein tyrosine phosphatase 1B inhibitor in central insulin resistance and associated cognitive deficits. Brain Research Bulletin, 2021, 171, 113-125.	3.0	3
22	Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review. Tissue and Cell, 2021, 70, 101497.	2.2	33
23	Promising traditional Indian medicinal plants for the management of novel Coronavirus disease: A systematic review. Phytotherapy Research, 2021, 35, 4456-4484.	5.8	33
24	Pharmacokinetic evaluation of Chalcone derivatives with antimalarial activity in New Zealand White Rabbits. BMC Research Notes, 2021, 14, 264.	1.4	5
25	Structural and conformational analysis of SARS CoV 2ÂN-CTD revealing monomeric and dimeric active sites during the RNA-binding and stabilization: Insights towards potential inhibitors for N-CTD. Computers in Biology and Medicine, 2021, 134, 104495.	7.0	14
26	Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide―and "teriflunomide―in Covid-19: A narrative review. European Journal of Pharmacology, 2021, 906, 174233.	3.5	27
27	Overcrowding an encumbrance for an emergency health-care system: A perspective of Health-care providers from tertiary care center in Northern India. Journal of Education and Health Promotion, 2021, 10, 5.	0.6	3
28	Efficacy and safety of inhaled nitric oxide in the treatment of severe/critical COVID-19 patients: A systematic review. Indian Journal of Pharmacology, 2021, 53, 236-243.	0.7	8
29	Antimicrobial resistance: An unseen threat prowling behind the COVID-19 outbreak. Indian Journal of Pharmacology, 2021, 53, 187-191.	0.7	0
30	Update on geographical variation and distribution of SARS-nCoV-2: A systematic review. Indian Journal of Pharmacology, 2021, 53, 310-316.	0.7	3
31	Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review. Indian Journal of Pharmacology, 2021, 53, 317-327.	0.7	18
32	Role of Iron Chelators in Mucormycosis. Indian Journal of Pharmacology, 2021, 53, 261-263.	0.7	4
33	COVID-19–associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis. Indian Journal of Pharmacology, 2021, 53, 499.	0.7	28
34	Social Pharmacology and its impact on clinics. Indian Journal of Pharmacology, 2021, 53, 437.	0.7	1
35	COMPARISON OF NON-ENDOSCOPIC SCORES FOR THE PREDICTION OF OUTCOMES IN PATIENTS OF UPPER GASTROINTESTINAL BLEED IN AN EMERGENCY OF A TERTIARY CARE REFERRAL HOSPITAL: A PROSPECTIVE COHORT STUDY. Arquivos De Gastroenterologia, 2021, 58, 534-540.	0.8	2
36	<i>In Silico</i> Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations. MSystems, 2020, 5, .	3.8	24

#	Article	IF	Citations
37	Premature graying of hair: Risk factors, coâ€morbid conditions, pharmacotherapy and reversalâ€"A systematic review and metaâ€analysis. Dermatologic Therapy, 2020, 33, e13990.	1.7	7
38	Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study. International Journal of Antimicrobial Agents, 2020, 56, 106224.	2.5	13
39	Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review. Life Sciences, 2020, 258, 118207.	4.3	14
40	Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. Journal of Molecular Graphics and Modelling, 2020, 101, 107716.	2.4	63
41	A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV. Virologica Sinica, 2020, 35, 290-304.	3.0	56
42	Virological and clinical cure in COVIDâ€19 patients treated with hydroxychloroquine: A systematic review and metaâ€analysis. Journal of Medical Virology, 2020, 92, 776-785.	5.0	178
43	Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis. Indian Journal of Pharmacology, 2020, 52, 535.	0.7	20
44	COVID-19 pandemic: A review based on current evidence. Indian Journal of Pharmacology, 2020, 52, 117.	0.7	44
45	Update on the target structures of SARS-nCoV-2: A systematic review. Indian Journal of Pharmacology, 2020, 52, 142.	0.7	41
46	Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Indian Journal of Pharmacology, 2020, 52, 313-323.	0.7	18
47	Pattern of clinical research in the era of COVID-19 pandemic: A new learning experience for the present as well as future. Indian Journal of Pharmacology, 2020, 52, 249-253.	0.7	1
48	Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian Journal of Pharmacology, 2020, 52, 414.	0.7	24
49	Presence of allele CYP3A4*16 does not have any bearing on carbamazepine-induced adverse drug reactions in North Indian people with epilepsy. Indian Journal of Pharmacology, 2020, 52, 378.	0.7	1
50	Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unkown. Indian Journal of Pharmacology, 2020, 52, 75.	0.7	2
51	Negative geotaxis: An early age behavioral hallmark to VPA rat model of autism. Annals of Neurosciences, 2019, 26, 25-31.	1.7	32
52	CYP2E1 activity and children with obesity: possible confounding factors. British Journal of Clinical Pharmacology, 2019, 85, 457-457.	2.4	2
53	Drugs in sport: The curse of doping and role of pharmacologist. Indian Journal of Pharmacology, 2019, 51, 1.	0.7	9
54	Positive list of antibiotics and food products: Current perspective in India and across the globe. Indian Journal of Pharmacology, 2019, 51, 231.	0.7	8

#	Article	IF	CITATIONS
55	Emerging antimicrobial resistance and newer tools to address the resistance. Indian Journal of Pharmacology, 2019, 51, 291.	0.7	3
56	Artificial intelligence in pharmacovigilance: Practical utility. Indian Journal of Pharmacology, 2019, 51, 373.	0.7	14
57	Novel therapeutic targets for amyotrophic lateral sclerosis. Indian Journal of Pharmacology, 2019, 51, 418.	0.7	13
58	Newer potential pharmacological targets for autism spectrum disorder. Indian Journal of Pharmacology, 2019, 51, 284.	0.7	1
59	Collaborative research in modern era: Need and challenges. Indian Journal of Pharmacology, 2019, 51, 137.	0.7	36
60	Pattern of pharmacological research from the last six decades. Indian Journal of Pharmacology, 2019, 51, 85.	0.7	0
61	Biovigilance: A global perspective. Perspectives in Clinical Research, 2019, 10, 155.	1.0	4
62	Targeted spontaneous reporting on drug safety alerts issued by pharmacovigilance programme of India: A new origin of pharmacovigilance in India. Journal of Pharmacology and Pharmacotherapeutics, 2019, 10, 33.	0.4	0
63	Specifically targeted antimicrobial peptides: A new and promising avenue in selective antimicrobial therapy. Indian Journal of Pharmacology, 2018, 50, 1.	0.7	13
64	Comparative effect of manuka honey on anaerobic parasitic protozoans with standard drug therapy under in vitro conditions: A preliminary study. Indian Journal of Pharmacology, 2018, 50, 197.	0.7	9
65	Intellectual property rights and Indian pharmaceutical industry: Present scenario. Indian Journal of Pharmacology, 2018, 50, 57.	0.7	5
66	CAN DEVELOPMENTAL, BEHAVIOURAL AND BIOCHEMICAL AND MOLECULAR PARAMETERS PREDICT LEVEL OF SUSCEPTIBILITY TO EPILEPTIC SEIZURES IN SUBJECTS WITH ASD: INSIGHT FROM A RAT MODEL OF ASD. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-1-83.	0.0	0
67	Connectomics: A pharmacologic viewpoint. Indian Journal of Pharmacology, 2018, 50, 299.	0.7	0
68	A study to determine Pharmacogenomic predictors of efficacy and safety of Azathioprine therapy in patients with IBD. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-14-22.	0.0	0
69	Withania somnifera root extract ameliorates valproic acid induced neurochemical and histopathological impairment in autistic rats. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-1-76.	0.0	0
70	Amelioration of antidepressant behavior by Granulocyte colony stimulating factor (GCSF) in depressed rats: Exploring the preclinical role of brain derived neurotrophic factor (BDNF) and neurotransmitters. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR6-5.	0.0	0
71	Modulation of endocannabinoid system: Success lies in the failures. Indian Journal of Pharmacology, 2018, 50, 155.	0.7	1
72	Congenital malformation and autism spectrum disorder: Insight from a rat model of autism spectrum disorder. Indian Journal of Pharmacology, 2017, 49, 243.	0.7	6

#	Article	IF	CITATIONS
73	Are your capsules vegetarian or nonvegetarian: An ethical and scientific justification. Indian Journal of Pharmacology, 2017, 49, 401-404.	0.7	3
74	Three-dimensional drugs: A new era in the pharmaceutical development. Indian Journal of Pharmacology, 2017, 49, 417.	0.7	4
75	An urgent need of experimental animal model of autism in drug development. Annals of Neurosciences, 2015, 22, 44-9.	1.7	17
76	Current scenario in inflammatory bowel disease: Drug development prospects. Pharmacological Reports, 2015, 67, 224-229.	3.3	12
77	A prospective study to evaluate awareness about medication errors amongst health-care personnel representing North, East, West Regions of India. International Journal of Applied & Basic Medical Research, 2014, 4, 43.	0.5	10
78	Granulocyte-colony stimulating factor improves Parkinson′s disease associated with co-morbid depression: An experimental exploratory study. Indian Journal of Pharmacology, 2013, 45, 612.	0.7	13
79	Can propofol cause seizures? an experimental study. Neurosciences, 2011, 16, 285-6.	0.1	0
80	Evaluation of propofol effect in altering pentylenetetrazol induced seizure threshold in TNBS colitis models in rats. FASEB Journal, 2009, 23, 947.5.	0.5	0
81	Computational attributes of protein kinase-C gamma C2-domain & Dirtual screening for small molecules: elucidation from meta-dynamics simulations & Dirtual screenergy calculations. Journal of Biomolecular Structure and Dynamics, 0, , 1-12.	3.5	2